Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAPGEF4 | Q8WZA2 | 2/20 | 0.53 |
| ▸ | NR3C1 | P04150 | 12/20 | 0.52 |
| ▸ | NR3C2 | P08235 | 3/20 | 0.52 |
| ▸ | PGR | P06401 | 2/20 | 0.50 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.47 |
| ▸ | GAA | P10253 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.40 |
| ▸ | ENPP3 | O14638 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4066654 | 0.84 | NR3C1 (0.72) | RAPGEF4NR3C1NR3C2PGRMEN1 | |
| SCHEMBL3642364 | 0.83 | NR3C1 (0.71) | RAPGEF4NR3C1NR3C2PGRMEN1 | |
| SCHEMBL3679725 | 0.80 | NR3C1 (0.53) | RAPGEF4NR3C1NR3C2PGRMEN1 | |
| SCHEMBL3640587 | 0.78 | NR3C1 (0.46) | NR3C1NR3C2PGR | |
| SCHEMBL3641963 | 0.74 | NR3C1 (0.53) | RAPGEF4NR3C1NR3C2PGRMEN1 | |
| SCHEMBL3643707 | 0.74 | NR3C1 (0.53) | NR3C1NR3C2PGRMEN1KMT2A | |
| SCHEMBL13810483 | 0.71 | NR3C1 (0.53) | RAPGEF4NR3C1NR3C2PGRMEN1 | |
| SCHEMBL3646346 | 0.70 | MAPT (0.54) | RAPGEF4NR3C1NR3C2PGRMEN1 | |
| SCHEMBL3644531 | 0.70 | NR3C1 (0.52) | RAPGEF4NR3C1NR3C2PGRMEN1 | |
| SCHEMBL3645834 | 0.70 | NR3C1 (0.40) | NR3C1NR3C2PGRGAAMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100317863-A1 | Glucocorticoid Mimetics, Methods of Making Them, Pharmaceutical Compositions and Uses Thereof | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-12-16 | — | — | US | claimed |
| US-20100317863-A1 | Glucocorticoid Mimetics, Methods of Making Them, Pharmaceutical Compositions and Uses Thereof | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-12-16 | — | — | US | disclosed |
| US-20100317863-A1 | Glucocorticoid Mimetics, Methods of Making Them, Pharmaceutical Compositions and Uses Thereof | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-12-16 | — | — | US | disclosed |
| US-20100317863-A1 | Glucocorticoid Mimetics, Methods of Making Them, Pharmaceutical Compositions and Uses Thereof | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-12-16 | — | — | US | disclosed |
| WO-2009015067-A2 | GLUCOCORTICOID MIMETICS, METHODS OF MAKING THEM, PHARMACEUTICAL COMPOSITIONS, AND USES THEREOF | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-01-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100317863-A1 | Glucocorticoid Mimetics, Methods of Making Them, Pharmaceutical Compositions and Uses Thereof | NR3C1, MC2R, NR3C2 | RAPGEF4 2194/4885NR3C1 1/4885NR3C2 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.